Key points are not available for this paper at this time.
Fig. S13. MS workflow used to identify MHC class I peptides increased by treatment with HDAC6 inhibitors or bortezomib.
Rana et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: